chronic hepatitis C genotype 1
Hepatology · 2012–2012
4decisions
3medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| boceprevir treatment, managed by an accredited treatment centre, of chronic hepatitis C genotype 1 infection in combination with peginterferon alfa and ribavirin in… | Jul 2012 | Recommended with restriction | unclear |
| telaprevir Treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment naïve or have previously… | Jul 2012 | Recommended with restriction | unclear |
| telaprevir Treatment of chronic genotype 1 hepatitis C in combination with peginterferon-alfa and ribavirin in adult patients aged 18 years or older with compensated… | Mar 2012 | Recommended with restriction | unclear |
| boceprevir and ribavirin and peginterferon alfa-2b Treatment of chronic hepatitis C genotype 1 infection in adult patients (18 years and older) with compensated liver disease who are previously untreated or who… | Nov 2012 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.